Serum biomarkers identified as potential predictors of baricitinib response in juvenile idiopathic arthritis
Anti-CD38 antibody CM313 demonstrated manageable safety and encouraging efficacy in systemic lupus erythematosus
Nipocalimab demonstrated significant efficacy in moderate-to-severe Sjögren’s disease in phase 2 trial
JAK inhibitors associated with modestly increased malignancy risk compared to biologics in rheumatoid arthritis patients
High-dose omega-3 supplementation improved fibromyalgia pain measures through alterations in serum magnesium and calcium levels
